Meet our researchers: Ghazaleh Eskandari-Sedighi, University of Alberta
Alzheimer Society of Canada
by
1M ago
Dr. Ghazaleh Eskandari-Sedighi from Dr. Matthew Macauley’s group at the University of Alberta talks about her research on elucidating the role of human CD33 protein in Alzheimer's disease pathogenesis. This project was funded by the Alzheimer Society Research Program (ASRP) in 2022 ..read more
Visit website
[Updated] Your questions, answered: What should Canadians know about Donanemab (Kisunla™)
Alzheimer Society of Canada
by
3M ago
On July 2, 2024, the United States Food and Drug Administration granted full approval to the drug donanemab (brand name Kisunla). Here’s what people in Canada might want to know about it ..read more
Visit website
[Updated] Your questions, answered: What should Canadians know about lecanemab’s full U.S. FDA approval?
Alzheimer Society of Canada
by
9M ago
On July 6, 2023, the United States Food and Drug Administration granted full approval to the drug lecanemab (brand name Leqembi). This drug aims to slow the progress of Alzheimer's disease. Health Canada began to review the drug in May 2023 ..read more
Visit website
‘Landmark’ study stresses urgent need to work collaboratively toward equity, diversity and inclusion in research, prevention and care
Alzheimer Society of Canada
by
9M ago
In Canada, we are in danger of failing the rapidly growing number of people living with dementia and their care partners if services and supports are not tailored to their unique needs, according to a new study released today by the Alzheimer Society of Canada ..read more
Visit website
The IG Wealth Management Walk for Alzheimer's
Alzheimer Society of Canada
by
11M ago
When you participate in the IG Wealth Management Walk for Alzheimer's, you join thousands of Canadians who want to see a world without Alzheimer’s disease and other dementias ..read more
Visit website
Knowledge translation grants propel cutting-edge dementia research into impact
Alzheimer Society of Canada
by
1y ago
Alzheimer Society of Canada and Brain Canada Foundation Announce KTE Accelerator Grant Recipients ..read more
Visit website
Bredesen Protocol offers false hope of reversing Alzheimer’s disease
Alzheimer Society of Canada
by
1y ago
A program that claims to reverse Alzheimer’s disease is growing in popularity, despite lack of evidence that it works. Learn more about the Bredesen protocol and its claims ..read more
Visit website
Your questions, answered: What should Canadians know about donanemab’s full trial results release?
Alzheimer Society of Canada
by
1y ago
On July 17, 2023, American drug company Eli Lilly and Company released full results from a Phase 3 trial of donanemab, a drug that aims to target Alzheimer’s disease. Here’s what people in Canada might want to know about it ..read more
Visit website
Your questions, answered: What should Canadians know about lecanemab’s full U.S. FDA approval?
Alzheimer Society of Canada
by
1y ago
On July 6, 2023, the United States Food and Drug Administration granted full approval to the drug lecanemab (brand name Leqembi). This drug aims to slow the progress of Alzheimer's disease. Health Canada began to review the drug in May 2023 ..read more
Visit website
Your questions, answered: What should Canadians know about donanemab’s latest drug trial results?
Alzheimer Society of Canada
by
1y ago
On May 3, 2023, American drug company Eli Lilly and Company released some results from a Phase 3 trial of donanemab, a drug that aims to target Alzheimer’s disease. Here’s what people in Canada might want to know about it ..read more
Visit website

Follow Alzheimer Society of Canada on FeedSpot

Continue with Google
Continue with Apple
OR